1. The EBNA1-IgA antibody test is a screening test only. It should not be used alone as a diagnostic tool for nasopharyngeal carcinoma (NPC).
2. Sensitivity (from studies) of iFlash EBNA1-IgA in different NPC patient groups: Total (89.6%), early NPC (86.4%) and advanced NPC (90.4%). Specificity of the test is 94.4%.2
Sources:
1. iFlash EBNA IgA CLIA reagent kit package insert. 04-07-2020.
2. Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma. Journal of Cancer. 2020;11(24): 7176-7183.